Luca Genovese to present Index findings on compliance and access to medicine
Tuesday, 16 May 2017
Pharmaceutical Industry Compliance Congress
On Tuesday 16 May, Luca Genovese will present research from the Access to Medicine Foundation during the morning plenary session of the 11th International Pharmaceutical and Medical Device Compliance Congress in Lisbon. His presentation will focus on Pharmaceutical Compliance and Access to Medicine: Findings from the 2016 Access to Medicine Index.
Luca will discuss how and why unethical behaviour along the pharmaceutical value chain – from clinical trials to marketing – undermines access to medicine. He will share findings from the 2016 Access to Medicine Index in this regard, which analysed the access-to-medicine strategies of 20 of the world’s largest pharmaceutical companies alongside their systems for monitoring and enforcing ethical standards.
The Congress will focus on themes of anti-corruption/anti-bribery programmes, data privacy, new marketplaces, transparency and the next generation of ethics and compliance programmes. Other speakers include:
- Nicola Bonucci – Director, Directorate for Legal Affairs at the Organisation for Economic Co-operation and Development (OECD)
- Thomas Cueni – Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- Marie-Claire Pickaert – Deputy Director General, Chief Financial Officer and Ambassador to the Medical Communities, European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Neill Stansbury – Co-founder and Director of the Global Infrastructure Anti-Corruption Centre; Chair, International Organization for Standardization Anti-Bribery Project Committee
The Congress is one of the key annual events worldwide on pharmaceutical compliance.
Market Influence & Compliance is one of the seven Technical Areas measured in the Access to Medicine Index. It looks at how companies interact with (or finance) external organisations, such as governments, patient groups and think tanks. It also examines evidence of breaches of ethical marketing codes, corruption and bribery, and how companies mitigate the risks of breaches occurring.